(Journal of Nutrition. 1999;129:1398S-1401S.)
© 1999 The American Society for Nutritional Sciences
Supplement
Concepts in Functional Foods: The Case of Inulin and Oligofructose1
Marcel B. Roberfroid
Université Catholique de Louvain, Department of Pharmaceutical Sciences, B-1200 Brussels, Belgium
 |
ABSTRACT
|
|---|
Recent advances in biosciences support the hypothesis that diet
modulates various body functions. Diet may maintain well-being and
reduce the risk of some diseases. Such discoveries have led to the
concept of "functional food" and the development of the new
discipline, i.e., "functional food science." A practical and
simple definition of a "functional food" is a food for
which a claim has been authorized. The food components to be
discussed as potential "functional food ingredients" are the
inulin-type fructans, i.e., chicory inulin and oligofuctose. The
targets for their effects are the colonic microflora, the
gastrointestinal physiology, the immune functions, the bioavailability
of minerals, the metabolism of lipids and colonic carcinogenesis.
Potential health benefits include reduction of risk of colonic
diseases, noninsulin-dependent diabetes, obesity, osteoporosis and
cancer. The documentation of such benefits requires scientific evidence
that must be evaluated in terms of "health claims." Previous
assessments have concluded that, in terms of "functional claims,"
strong evidence exists for a prebiotic effect and improved bowel habit.
The evidence for calcium bioavailability is promising, and positive
modulation of triglyceride metabolism is undergoing preliminary
evaluation. Scientific research still must be done to support any
"disease risk reduction claim," but sound hypotheses do already
exist for designing the relevant human nutrition trials.
KEY WORDS: functional food inulin prebiotic calcium bioavailability
 |
INTRODUCTION
|
|---|
Today, the industrialized countries are facing, among others, three
major challenges:
to control the cost of health care
to offer to their aging population a real opportunity to live, not only
longer, but also better
to provide to more and more "busy" consumers, a choice of healthy
processed or ready-to-eat foods
At the same time, progress in the biosciences supports the
hypothesis that, beyond providing nutrition, diet also may modulate
various functions in the body that are relevant to health. The concepts
in nutrition are changing from a past emphasis on the absence of
adverse effects to an emphasis on the promising use of foods to promote
a state of well-being, better health and reduction of the risk of
diseases. These concepts have recently become popular with consumers.
Indeed, although there are still many people who know little about
nutrition itself, consumer awareness of the subject and its
relationship to health is nevertheless growing appreciably. Finally,
advances in food science and technology are providing the food industry
with increasingly effective techniques to control and improve the
physical structure and the chemical composition of food products. There
is also a growing awareness of the additional benefits and market
potential for functional foods. Over the last decade, primarily in
Japan and in the United States, these challenges together with these
new concepts in nutrition have justified the development of
"functional foods."
 |
Functional foods
|
|---|
A food can be said to be "functional"
if it meets one of the following criteria: 1) [it]
contains a food component (being a nutrient or not) which affects
one or a limited number of function(s) in the body in a targeted way so
as to have positive effects (Bellisle et al. 1998
);
2) [it] has physiological or psychological effect
beyond the traditional nutritional effect (Clydesdale 1997
). Collectively, a functional food should have a relevant
effect on well-being and health or result in a reduction in disease
risk.
The component that makes the food "functional" can be either an
essential macronutrient if it has specific physiologic effects [such
as resistant starch or (n-3) fatty acids], or an essential
micronutrient if its intake is over and above the daily
recommendations. Additionally, it could be a food component even though
some of its nutritive value is not listed as "essential" (e.g.,
some oligosaccharides) or it is even of nonnutritive value (e.g., live
microorganisms or plant chemicals).
 |
The production of functional foods
|
|---|
A natural food product can be genuinely "functional" if it
contains food component(s) that modulate(s) function(s) in the body
that is (are) relevant to health. A food product can be made functional
in the following ways:
- By increasing the concentration of a natural component to
reach a concentration that is more likely to induce the expected
effects [e.g., fortification with a micronutrient to reach a daily
intake higher than the recommended daily intake but compatible with the
dietary guidelines for disease prevention Block (1993)
]
or by increasing the concentration of a nonnutritive component for
which data that demonstrate beneficial effects are available.
- By adding a component that is not normally present in most
foods, but for which beneficial effects have been demonstrated (e.g.,
non-vitamin antioxidants or prebiotic fructans).
- By replacing a component, usually a macronutrient whose intake
is usually excessive and thus has deleterious effects (e.g., fats) with
a component for which beneficial effects have been demonstrated, e.g.,
chicory inulin as Rafticreme (Franck-Frippiat 1993
).
- By improving the bioavailability of food components for which
beneficial effects have been demonstrated.
However, the demonstration of such beneficial effects requires a
strict scientific approach for which a strategy can be proposed. This
strategy must refer to a functional food science aimed at stimulating
research and development of functional foods based on a
"function-driven" approach, which is considered more
universal than a product-driven approach.
 |
The functional food science
|
|---|
The positive effects of a functional food can be either
maintenance and/or improvement of a state of well-being and health,
or reduction of the risk of a disease. The design and development of
functional foods is a key issue as well as a scientific challenge that
should rely on the following:
- Basic scientific knowledge relevant to functions that are
sensitive to modulation by food components; pivotal to maintenance of
well-being and health; linked, when altered, to a change in the
risk of a disease.
- The exploitation of this knowledge in the development of
markers that can be shown to be relevant to the key functions.
- A new generation of hypothesis-driven human intervention
studies that will include the use of these validated, relevant markers
and allow the establishment of effective and safe intakes.
- The development of advanced techniques for human studies that
are minimally invasive and applicable on a large scale.
The initial step in research and development of a functional food
is thus the identification of a specific and potentially beneficial
interaction between one or more components of the food and a genomic,
cellular, biochemical or physiologic function in the organism. This
step belongs to fundamental research and must lead to one or more
proposals for hypothetical mechanisms of the identified interaction. On
such a basis, a functional effect can then be defined and demonstrated
in relevant models. The conclusion of these experiments is a new
hypothesis with regard to the relevance of the functional effect to
human health, tested in strictly designed nutritional studies involving
appropriate volunteers. The demonstration of these effects must also
include a safety assessment. This evaluation is an absolute
prerequisite for functional food development.
A functional food will be of limited value in terms of health benefit
if it is not part of the diet. This is the opinion of G. Pascal, who,
in his presentation at the 1st East West Perspectives Conference on
Functional Foods (Pascal 1996
), stated clearly that:
functional foods must remain foods; they are not pills or
capsules but components of a diet or part of a food pattern recognized
as being beneficial for well being and health. It would probably
be more appropriate to speak of functional diet or even optimum
nutrition rather than functional food.
Among the miscellaneous functions that are relevant to the potential
functional effects of inulin and oligofructose are the following:
- The gastrointestinal functions, especially those associated
with a balanced colonic microflora, those mediated by the endocrine
activity of this organ, and those that depend on its immune activity,
control nutrient (in particular ions) bioavailability, or control stool
production, transit time and intestinal motility (Roberfroid 1996 and 1998
).
- The hormonal modulation, via the balance insulin/glucagon or
the production of gastrointestinal peptides, or the metabolism of the
macronutrients (especially carbohydrates and fatty acids) with, as
objective, reduced risk of syndrome X as well as cardiovascular
diseases. One example is the reduced hepatic lipogenesis induced by
chicory fructans (Fiordaliso et al. 1995
, Kok et al. 1996
).
 |
Communication to the public
|
|---|
The science base generated by the research and development in the
field of functional foods will serve to establish "health
claims," which can then be translated into messages for consumers.
According to Clydesdale (1997)
, a "health claim"
refers to a positive correlation (i.e., reduction in risk and/or
lessening of an adverse physiologic or psychological condition) between
a food substance in a diet and a disease or other health-related
condition. By reference to the strategy for research and development
presented above, these claims will refer to either functional effects
or disease risk reduction.
A functional effect refers to the positive consequence(s) of the
interaction(s) between a food component and specific genomic,
biochemical, cellular or physiologic function(s) without direct
reference to any health benefit or reduction of risk of a disease. For
example, inulin and oligofructose rebalance metabolic activities (e.g.,
lipid homeostasis), strengthen immune functions (immunostimulation),
restore or stabilize colonic microflora (e.g., selective stimulation of
bifidobacteria) and improve bioavailability of nutrients
(Roberfroid 1998
). Functional claims have already and
will in the future lead to new concepts in nutrition. Examples of such
new concepts are the prebiotics and synbitotics, colonic foods and
bifidogenic factors (Gibson and Roberfroid 1995
).
A disease risk reduction refers to the reduction of the risk of a
disease by consuming a specific component or ingredient or a mixture of
food component(s) or food ingredient(s). Examples include the reduction
of risk of cardiovascular disease, infections (e.g., intestinal
infections), atherosclerosis, liver diseases, diarrhea, constipation,
osteoporosis and syndrome X (e.g., noninsulin-dependent diabetes or
obesity). Even though it will depend on the particular disease risk to
be reduced, the demonstration of such health effects remains a very
difficult task and will require long-term experiments whose final
results are difficult to predict.
Both functional effects and disease risk reduction require the
demonstration of an effect in humans based on nutritional studies
designed according to protocols and evaluation criteria, which are not
necessarily these presently used in clinical studies for drug
development. Indeed, the target populations of these nutritional
studies are, in most cases, "healthy persons" or "persons
supposedly healthy" for whom the "usual" diet will be modified
in order to demonstrate a statistically, but also and perhaps more
importantly, biologically significant change in parameters/markers
indicative of a state of "well-being and good health." In the
vast majority of cases, these parameters/(bio)markers are yet to be
discovered and, certainly, validated.
 |
The case of inulin and oligofructose
|
|---|
Inulin-type fructans are composed of
ß-D-fructofuranoses attached by ß-21 linkages. The
first monomer of the chain is either a ß-D-glucopyranosyl
or ß-D-fructopyranosyl residue. They constitute a group
of oligosaccharides derived from sucrose that are isolated from natural
vegetable sources. Generally, the product with a degree of
polymerization (DP) from 2 to 60+ is labeled as inulin (Raftiline),
whereas oligofructose, which is produced by partial enzymatic
hydrolysis of inulin, is defined as DP < 10 (Raftilose). The
inulin from which the small molecular weight oligomers have been
eliminated is called inulin high performance (Raftiline HP).
The objective of the Inulin and Oligofructose Conference, 1998, was to
review the science base concerning the nutritional and health benefits
of inulin and oligofructose. Two major questions were proposed to the
participants to stimulate discussions. These questions were discussed
extensively in a recent review on "Dietary Fructans"
(Roberfroid and Delzenne 1998
).
- I. Does sufficient scientific evidence exist for functional claims
for inulin and oligofructose? The topics to be addressed are as
follows:
- A. The classification of inulin and oligofructose as dietary fiber based
on their resistance to digestion, followed by fermentation in the colon
leading to improvement of colonic functions (especially fecal bulking),
(Gibson et al. 1995
, Roberfroid et al. 1993
), as well as some systemic physiologic effects
(Roberfroid 1993
).
- B. The selective stimulation of bifidobacteria growth in the colonic
microbiota to support their classification as prebiotic. Of particular
interest is the question of the dose-effect relationship in a
complex ecosystem such as colonic microbiota because it may depend on
other factors such as the initial number of bifidobacteria
(Roberfroid et al. 1998
). This may lead to the
conclusion that, at the population level, the question of the dose is
of low relevance and that, on an average base, taking into account the
variability in the number of bifidobacteria in the human colonic flora,
doses of a 45g/d are efficient in stimulating the growth of these
bacteria classified as potentially beneficial for health (Gibson and Roberfroid 1995
). Further, as to the classification as
prebiotic, questions that remain to be answered are the following:
- the long-term persistence of the "bifidogenic" effect both
when continuing to consume an inulin/oligofructoserich diet and after
stopping;
- the interest, in term of functional effects, of the so-called
"synbiotic" approach, which combines both inulin or oligofructose
as prebiotic and a probiotic strain (Gibson and Roberfroid 1995
); and most importantly,
- the health benefits of having a colonic flora in which bifidobacteria
predominate (see below for a discussion on possible disease risk
reduction claims).
- C. The increased bioavailabilty of minerals, in particular, calcium.
- D. The stimulation of the immune system.
- E. The effects on lipid metabolism. Experimental data support the
hypothesis that oligofructose inhibits hepatic lipogenesis in rats and,
consequently, induces a significant hypotriglyceridemic effect. Because
a metabolic link has recently been demonstrated between insulin
resistance and the associated risk factors for atherosclerotic
cardiovascular disease, especially hypertriglyceridemia, and because
hypertriglyceridemia itself may be a risk factor in atherogenesis,
these potential functional effects should be studied carefully in
humans, especially in conditions known to be associated with
hyperinsulinemia and hypertriglyceridemia (Aarsland et al. 1996
, Carlson et al. 1979
, Castelli 1986
, Taskinen 1993
).
- II. Does scientific evidence support disease-risk-reduction claims
for inulin-type fructans? For inulin and oligofructose,
"disease risk reduction claims" are, based on presently available
scientific information, which is only tentative; further research is
required to support and validate these claims. The most promising areas
for the development of such claims are the following:
- A. Constipation relief due to fecal bulking and possible effects on
intestinal motility (Kleessen et al. 1997
).
- B. Inhibition of diarrhea, especially when it is associated with
intestinal infections. This may be related directly to the possible
inhibitory effect of bifidobacteria on both gram-positive and
gram-negative bacteria, which has been reported by Wang and Gibson
(Gibson and Wang 1994
, Wang 1993
).
- C. Reduction of risk of osteoporosis if the improvement of the
bioavailability of Ca, by inulin and oligofructose, is followed by a
more physiologic change in bone mineral density and peak bone mass.
- D. Reduction of the risk of atherosclerotic cardiovascular disease
associated with dyslipidemia, especially hypertriglyceridemia, and
insulin resistance, which, in particular, is known to be associated
with hypercaloric high carbohydrate feeding regimens (Aarsland et al. 1996
).
- E. Reduction of the risk of colon carcinogenesis via an inhibition of the
development of aberrant crypt foci and other surrogate markers
(Gallaher et al. 1996
, Koo and Rao 1991
,
Reddy et al. 1997
, Rowland et al. 1998
)
and/or reduction in the growth rate of tumors (Taper et al. 1997
). In the strategy for functional food development
described above, these cancer-inhibitory effects in experimental
animals could correspond to the first step, i.e., identification of
effects. Because of their implications in health, these effects will
have to be evaluated carefully in relevant human studies.
 |
CONCLUSION
|
|---|
The development of functional foods is a unique opportunity to
contribute to the improvement of the quality of food and consumer
health and well-being. In that context, inulin and oligofructose
are natural products that may become classified in the future as
functional food ingredients for which validated health claims may
become authorized. Only a rigorous scientific approach that yields
sound and reliable data will justify any claim. Collectively, this
information is clearly a challenge for both the scientific community
and the food industries. The major challenge to these partners is to
give the consumers the guarantee that these new food products are not
just a new opportunity for more profits, but genuine progress toward
allowing them better control of their health. This conference is about
the "Nutritional and Health Benefits of Inulin and Oligofructose"
and provides a unique opportunity to evaluate present knowledge and
propel the science forward.
 |
FOOTNOTES
|
|---|
1 Presented at the conference Nutritional and
Health Benefits of Inulin and Oligofructose held May 1819, 1998 in
Bethesda, MD. This symposium was supported in part by educational
grants from the National Institutes of Health Office of Dietary
Supplements, the U.S. Department of Agriculture and Orafti Technical
Service. Published as a supplement to The Journal of
Nutrition. Guest editors for the symposium publication were
John A. Milner, The Pennsylvania State University, and Marcel
Roberfroid, Louvain University, Brussels, Belgium. 
 |
REFERENCES
|
|---|
1.
Aarsland A., Chinkes D., Wolfe R. R. Contributions of de novo synthesis of fatty acids to total VLDL-triglyceride secretion during prolonged hyperglycemia/hyperinsulinemia in normal man. J. Clin. Investig. 1996;98:2008-2017[Medline]
2.
Bellisle F., Diplock A. T., Hornstra G., Koletzkos B., Roberfroid M., Salminen S., Saris W.H.M. Functional food science in Europe. Br. J. Nutr. 1998;80:S1-S193
3.
Block G. Micronutrients and cancer: time for actions?. J. Natl. Cancer Inst. 1993;85:846-848[Free Full Text]
4.
Carlson L. A., Bottiger L. E., Ahfeldt P. E. Risk factors for myocardial infarction in the Stockholm prospective study: a 14 year follow-up focussing on the role of plasma triglycerides and cholesterol. Acta Med. Scand. 1979;206:351-360[Medline]
5.
Castelli W. P. The triglyceride issue: a view from Framingham. Am. Heart J. 1986;112:432-437[Medline]
6.
Clydesdale F. A proposal for the establishment of scientific criteria for health claims for functional foods. Nutr. Rev. 1997;55:413-422[Medline]
7.
Fiordaliso M. F., Kok N., Desager J. P., Goethals F., Deboyser D., Roberfroid M. B., Delzenne N. Dietary oligofructose lowers triglycerides, phospholipids, and cholesterol in serum and very low density lipoproteins of rats. Lipids 1995;30:163-167[Medline]
8.
Franck-Frippiat, A. (1993) Rafticreaming: the new process
allowing to turn fat into dietary fiber. FIE `92: Conference
Proceedings, pp. 193197. Maarssen Expoconsult Publ.,The Netherlands.
9.
Gallaher D. D., Stallings W. H., Blessing L., Busta F. F., Brady L. J. Probiotics, cecal microflora, and aberrant crypts in the rat colon. J. Nutr. 1996;126:1362-1371
10.
Gibson G.R., Beatty E. R., Wang X., Cummings J. H. Selective stimulation of Bifidobacteria in the human colon by oligofructose and inulin. Gastroenterology 1995;108:975-982[Medline]
11.
Gibson G.R., Roberfroid M.B. Dietary modulation of the human colonic microflora: introducing the concept of prebiotics. J. Nutr. 1995;125:1401-1412
12.
Gibson G. R., Wang X. Inhibitory effects of bifidobacteria on other colonic bacteria. J. Appl. Bactriol. 1994;65:103-111
13.
Kleessen B., Sykura B., Zunft H. J., Blaut M. Effects of inulin and lactose on faecal microflora, microbial activity, and bowel habit in elderly constipated persons. Am. J. Clin. Nutr. 1997;65:1397-1402[Abstract/Free Full Text]
14.
Kok N., Roberfroid M., Robert A., Delzenne N. Involvement of lipogenesis in the lower VLDL secretion induced by oligofructose in the rat. Br. J. Nutr. 1996;76:881-890[Medline]
15.
Koo M., Rao V. Long term effect of bifidobacteria and neosugar on precursor lesions of colonic cancer in mice. Nutr. Cancer 1991;16:249-257[Medline]
16.
Pascal G. Functional foods in the European Union. Nutr. Rev. 1996;54:S29-S32[Medline]
17.
Reddy B. S., Hamid R., Rao C. V. Evaluation of oligosaccharides for potential chemopreventive properties in colon carcinogenesis using aberrant crypt foci. Carcinogenesis 1997;18:1371-1374[Abstract/Free Full Text]
18.
Roberfroid M. Dietary fiber, inulin and oligofructose: a review comparing their physiological effects. Crit. Rev. Food Sci. Nutr. 1993;33:103-148[Medline]
19.
Roberfroid M. B. Functional effects of food components on the gastrointestinal system. Nutr. Rev. 1996;54:S38-S42[Medline]
20.
Roberfroid, M. B. (1998) Background paper for a
workshop on the role of intestinal flora and nutrient bioavailability.
BIOAVAILABILITY 97: Wageningen, The Netherlands, 2528 May, 1997.
21.
Roberfroid M. B., Delzenne N. Dietary fructans. Annu. Rev. Nutr. 1998;18:117-143[Medline]
22.
Roberfroid M. B., Gibson G. R., Delzenne N. Biochemistry of oligofructose, a non-digestible fructo-oligosaccharide: an approach to estimate its caloric value. Nutr. Rev. 1993;51:137-146[Medline]
23.
Roberfroid M. B., Van Loo J.A.E., Gibson G.R. The bifidogenic nature of chicory inulin and its hydrolysis products. J. Nutr. 1998;128:11-19[Abstract/Free Full Text]
24.
Rowland I. R., Rumney C. J., Coutts J. T., Lievense L. C. Effect of Bifidobacterium longum and inulin on gut bacterial metabolism and carcinogen-induced crypt foci in rats. Carcinogenesis 1998;19:281-285[Abstract/Free Full Text]
25.
Taper H., Delzenne N., Roberfroid M. B. Growth inhibition of transplantable mouse tumors by non digestible carbohydrates. Int. J. Cancer 1997;71:1109-1112[Medline]
26.
Taskinen M. R. Hyperinsulinism and dyslipidemias as coronary heart disease risk factors in NIDDM. Adv. Exp. Med. Biol. 1993;334:295-300[Medline]
27.
Wang, X. (1993) Comparative Aspects of Carbohydrate
Fermentation by Colonic Bacteria. Doctoral thesis, University of
Cambridge, Cambridge, UK.
Copyright © 1999 by American Society for Nutrition